Features

Look for profits with Regeneron

Regeneron, a US biotech company, specialises in treating eye diseases. But it’s far from a one-trick pony.

946_MW_P32_Companies

AMD is the main cause of blindness in over-65s

Diabetic eye disease and age-related macular degeneration (AMD) are becoming increasingly common. AMD is especially serious since it damages the central area of the retina, making it difficult to read and watch television; it is the leading cause of blindness in people over 65. Eylea, a drug produced by US biotech Regeneron (Nasdaq: REGN), is saving the sight of millions of people suffering from these conditions.

It is the market leader, notching up annual sales of $6.7bn a year, helped by its dosing regimen of injections every eight weeks compared to competing drug Lucentis's every four weeks. Analysts are pencilling in peak sales of $8bn a year for Eylea.

A full pipeline

Regeneron develops treatments for six main therapeutic areas: ophthalmology, inflammatory diseases, cardiovascular and metabolic diseases, oncology, pain and rare diseases. Beyond Eylea, approved and marketed drugs include Dupixent for atopic dermatitis and asthma, Zaltrap for metastatic colorectal cancer and Arcalyst for rare autoimmune conditions. Some of Regeneron's revenues appear as partnership revenues; these include non-US Eylea revenues through Bayer and sales of Zaltrap through Sanofi. The Sanofi sales totalled $1.4bn in 2018 with Eylea $6.75bn (US $4.1bn) and others $29.5m.

As with all biotech companies, Regeneron's potential is determined by the approved drugs likely to emerge from its pipeline. One of its most interesting pipeline areas is an immuno-oncology platform, with one drug, Libtayo, hitherto approved and marketed. Regeneron has nine of its 16 Phase I clinical trials in immuno-oncology with another two in later phases one each in Phase II and Phase III (the final stage of clinical testing, before a drug is submitted to regulators for approval).

Drugs close to approval

All but one of the 29 pipeline clinical trials are of antibody drugs based on antibodies developed in-house. A total of four new molecules entered clinical trials in 2018 and 4-6 new antibody molecules are expected to enter clinical trials during 2019 demonstrating that research and development is paying off. The Regeneron genetics centre, meanwhile, continues to make discoveries including a new genetic variant that protects against chronic liver disease.

A blockbuster machine going cheap

Regeneron (NASDAQ: REGN)
Investment measureInvestment ratio
Share price$3222020 p/e ratio12.8
Market value$34.5bnCash$5.6bn
Recent results20172018Change
Revenue$5.87bn$6.71bn+14.3%
Operating profit$2.08bn$2.53bn+21.6%*
R&D$2.08bn$2.19bn+5.3%
Earnings per share$16.30$22.80+39.9%

earnings per share (EPS)

Research and development (R&D) is a very high 32.6% of sales compared to most biopharma companies which typically devote 15%-25% of sales to R&D (Merck, for example, invested 23% in 2018 and Pfizer 14.9%).

Regeneron also has a healthy cash balance of $5.6bn, which it can use both for advancing the pipeline and for acquiring smaller biotechs. After Eylea, Dupixent is the second-highest selling approved drug with sales of $374m in the first quarter of 2019. It is thus already a blockbuster drug (one with annual sales over $1bn). Dupixent was approved for asthma late last year and has just been given the green light to treat adolecent atopic dermatitis. It could soon be approved for chronic rhinitis too.

These approvals suggest increasing revenue through to at least 2020. Analysts project EPS for Regeneron of $23.1 for 2019, rising to $25.2 for 2020. This gives a forward P/E of 12.8 for 2020 at the recent share price of $322.

Regeneron has one super-blockbuster ($10bn+ sales), Eylea, and one blockbuster, Dupixent, already on the market, five other approved drugs, a substantial cash pile and a pipeline based on its own antibodies with impressive potential in immuno-oncology.

It has proprietary technologies for therapeutic antibody production and gene therapy. The main risk with this stock is of late-stage clinical trial failures that reduce the prospects of replacing and enhancing Eylea revenue should stronger competitors to Eylea emerge and for when Eylea's patents expire. But the forward price/earnings ratio of 12.8 makes Regeneron an attractive addition to your biopharma portfolio.

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021